Drug intelligence / Profile preview

99mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val

Development stage
Preclinical
Lead developer
China Pharmaceutical University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptides
Administration
Intravenous
01

Overview

99mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val (also known as 99mTc-HYNIC-I0) is a novel, fibroblast growth factor receptor 4 (FGFR4)-targeted radiopharmaceutical probe developed for the imaging of hepatocellular carcinoma (HCC). The probe consists of the octapeptide fragment Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val (I0), which is derived from the sequence of fibroblast growth factor 19 (FGF19)—an endogenous ligand of FGFR4 with high binding affinity. This peptide is conjugated to the bifunctional chelator hydrazinonicotinamide (HYNIC) and radiolabeled with technetium-99m (99mTc) using ethylenediamine-N,N'-diacetic acid (EDDA) and tricine as co-ligands. In preclinical studies, 99mTc-HYNIC-I0 demonstrated high radiochemical purity, favorable in vitro stability, and specific cellular uptake in FGFR4-expressing HepG2 cells. In vivo SPECT/CT imaging in tumor-bearing mice showed clear tumor visualization with high tumor-to-background ratios, suggesting its potential as a diagnostic imaging agent for FGFR4-positive hepatocellular carcinoma.

Other names
99mTc-HYNIC-I099mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-ValHYNIC-I0HYNIC-I-0HYNIC-I 0HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val
02

Identity

Drug type
Peptides
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesGamma Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
hepatocellular carcinoma (HCC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • China Pharmaceutical UniversityLead developer
07

Competitive landscape

Drugs on the same target
43
Drugs in the lead indication
966

Lead indication: hepatocellular carcinoma (HCC)

Most advanced in the lead indication

  1. lenvatinibApproved
  2. ADC 3Approved
  3. atezolizumabApproved
  4. bevacizumabApproved
  5. cabozantinibApproved

Beyond the preview

Go deeper on 99mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val.

Work on 99mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call